膵がん治療薬市場：タイプ、製品、エンドユーザー別-2025-2030年の世界予測

膵がん治療薬市場の2023年の市場規模は46億7,000万米ドルで、2024年には51億4,000万米ドルに達すると予測され、CAGR 9.95％で成長し、2030年には90億9,000万米ドルに達すると予測されています。

膵がん治療薬市場は、膵臓の悪性細胞を標的とする治療法の開拓に重点を置く腫瘍学分野の重要なセグメントです。この市場の範囲は、標的療法、化学療法、放射線療法、免疫療法や遺伝子療法などの新たな選択肢にまで広がっています。この市場の成長は、膵臓がんの有病率の上昇、人口の高齢化、認知度の向上、医学研究の進歩によってもたらされます。これらの治療薬の必要性は、膵臓がんに関連する歴史的に低い生存率と、患者の転帰を改善する革新的な治療に対する緊急の必要性から生じています。主なエンドユーザーには、病院、がん研究センター、調査に携わる製薬会社などが含まれます。

市場に影響を与える主な成長要因としては、診断手順の技術的進歩、強力な医薬品パイプライン、研究開発投資の増加、がん研究を支援する政府の取り組みなどが挙げられます。さらに、バイオテクノロジー企業と研究機関のコラボレーションは、特に個別化医療とバイオマーカー探索において潜在的な機会を生み出しています。こうした機会を活用するための提言としては、戦略的パートナーシップ、精密医療などのニッチ分野への注力、有望な治療法の臨床試験の加速などが挙げられます。

しかし、この市場は、高い治療費、厳しい規制当局の承認、早期診断における課題といった限界に直面しており、これらは患者の治療へのアクセスに影響を及ぼしています。競争企業間の敵対関係や医薬品開発への多大な時間的投資が、さらなるハードルとなっています。企業は、より侵襲性の低い治療法の開発、ドラッグデリバリーシステムの改善、新規併用療法の探索に研究努力を集中することで、イノベーションを推進することができます。さらに、AIやビッグデータ解析を活用して創薬効率を高めることも有望です。

結論として、膵がん治療薬市場には、技術的進歩や共同作業を通じて成長する大きな機会がある一方で、コストの障壁や規制上の課題に対処することが極めて重要になります。治療方法の革新とデータ主導のアプローチが大きなブレークスルーの道を開き、ビジネスの成長と患者ケアの向上を促進すると思われます。

市場力学：急速に進化する膵がん治療薬市場の主要市場インサイトを公開

膵がん治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で増加する膵臓がん患者の有病率
  • 膵がん治療オプションへのアクセスを拡大するための政府の取り組み
• 市場抑制要因
  • 副作用による医薬品回収と償還オプションの利用困難
• 市場機会
  • 膵がん治療薬の有効性を向上させるための調査イニシアティブと進歩
  • 膵がん治療の承認と希少がん治療薬の承認
• 市場の課題
  • 膵がん治療オプションの限界と合併症、訓練を受けた医療専門家の不足

ポーターの5つの力：膵がん治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：膵がん治療薬市場における外部からの影響の把握

外部マクロ環境要因は、膵がん治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析膵がん治療薬市場における競合情勢の把握

膵がん治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス膵がん治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、膵がん治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で膵臓がんの罹患率が上昇
    • 膵臓がん治療選択肢へのアクセス拡大に向けた政府の取り組み
  • 抑制要因
    • 有害な医薬品の回収と償還オプションの利用の難しさ
  • 機会
    • 膵がん治療薬の有効性を向上させるための調査イニシアチブと進歩
    • 膵臓がん治療薬の承認とがん治療のための希少疾病用医薬品の承認
  • 課題
    • 膵臓がん治療の選択肢の限界と合併症、そして訓練を受けた医療専門家の不足
• 市場セグメンテーション分析
  • タイプ：外分泌膵臓がんの急速な進行による治療オプションの迅速な展開の必要性
  • 製品：化学療法治療オプションの承認数を拡大
  • 最終用途：膵臓がん治療のための調査機関における連携と研究開発活動の拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 膵がん治療薬市場：タイプ別

• 内分泌膵臓がん
• 外分泌膵臓がん

第7章 膵がん治療薬市場：製品別

• 化学療法
• 遺伝子治療
• 免疫療法
• 放射線治療
• 手術
• 標的療法

第8章 膵がん治療薬市場：最終用途別

• がんセンター/クリニック
• 病院
• 調査機関

第9章 南北アメリカの膵がん治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の膵がん治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの膵がん治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • トリシューラ・セラピューティクス、転移性膵臓がんの第一選択治療患者を対象に抗CD39抗体TTX-030の第2相試験を開始
  • リサタが膵臓がん治療薬として希少疾病用医薬品の指定を受ける
  • PanCANが新たな先進調査への投資を発表
  • プレステージ・バイオファーマとイマジオン・バイオシステムズが膵臓がんの早期診断プラットフォームの開発で提携契約を締結
  • TriSalus Life Sciences、MedTech Acquisition Corporationとの合併を完了
  • ブリストルマイヤーズスクイブ、ミラティセラピューティクスの買収により腫瘍学ポートフォリオを強化・多様化
  • アステラス製薬とポセイダ・セラピューティクス、がん細胞治療の革新に向けたポセイダの取り組みを支援する戦略的投資を発表
  • FDA、NRG1+膵臓がんに対するゼノクツズマブを画期的治療薬に指定
  • FDA、TMEファーマの膵臓がん治療試験のINDを承認
  • ジェネシスケア、リーヘルス地域がんセンターでViewRay MRIdian MRI誘導放射線治療システムを導入
  • 膵臓がん研究に300万米ドルの国家補助金
  • Leap TherapeuticsがFlame Biosciencesを買収
  • Caladrius BiosciencesとCend Therapeuticsが合併の完了とLisata Therapeuticsの設立を発表
  • フェス・セラピューティクス、がんの臨床試験を進めるために4,700万米ドルを調達
  • アストラゼネカ・メルクのリムパーザが膵臓がん治療薬としてEUの承認を取得

企業一覧

• Abbvie Inc.
• Amgen Inc.
• Ascentage Pharma Group
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• C.H. Boehringer Sohn AG & Co. KG
• Carl Zeiss AG
• Carrick Therapeutics Limited
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Faeth Therapeutics, Inc.
• FUJIFILM Holdings Corporation
• GE HealthCare Technologies, Inc.
• GenesisCare
• GlaxoSmithKline PLC
• Hetero Healthcare Limited
• ImmunityBio, Inc.
• Innovent Biologics Inc.
• Johnson & Johnson Services, Inc.
• Lupin Limited
• Merck & Co., Inc.
• Mitsubishi Heavy Industries, Ltd.
• NGM Biopharmaceuticals, Inc.
• NovalGen
• Novartis AG
• PanTher Therapeutics, Inc.
• Pfizer, Inc.
• RenovoRx, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Zentalis Pharmaceuticals, Inc.

LIST OF FIGURES

• FIGURE 1. PANCREATIC CANCER THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. PANCREATIC CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. PANCREATIC CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PANCREATIC CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PANCREATIC CANCER THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY ENDOCRINE PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY EXOCRINE PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS/CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 148. PANCREATIC CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. PANCREATIC CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Pancreatic Cancer Therapeutics Market was valued at USD 4.67 billion in 2023, expected to reach USD 5.14 billion in 2024, and is projected to grow at a CAGR of 9.95%, to USD 9.09 billion by 2030.

The pancreatic cancer therapeutics market is a critical segment of the oncology sector, focused on developing treatments that target malignant cells in the pancreas. The scope of this market extends to targeted therapies, chemotherapy, radiation therapy, and emerging options such as immunotherapy and gene therapy. This market's growth is driven by the rising prevalence of pancreatic cancer, an aging population, increased awareness, and advancements in medical research. The necessity of these therapeutics stems from the historically low survival rate associated with pancreatic cancer and the urgent need for innovative treatments that improve patient outcomes. Major end-users include hospitals, cancer research centers, and pharmaceutical companies involved in R&D.

Key growth factors influencing the market include technological advances in diagnostic procedures, a robust pipeline of drugs, increasing investments in R&D, and government initiatives supporting cancer research. Additionally, collaborations between biotechnology firms and research institutions are creating potential opportunities, especially in personalized medicine and biomarker discovery. Recommendations to capitalize on these opportunities involve strategic partnerships, focusing on niche segments such as precision medicine, and accelerating clinical trials for promising therapies.

However, the market faces limitations such as high treatment costs, stringent regulatory approvals, and challenges in early diagnosis, which impact patient access to therapies. Competitive rivalry and significant time investments in drug development pose further hurdles. Firms can drive innovation by concentrating research efforts on developing less invasive treatments, improving drug delivery systems, and exploring novel combination therapies. Moreover, leveraging AI and big data analytics to enhance drug discovery efficiency is promising.

In conclusion, while the pancreatic cancer therapeutics market offers substantial opportunities for growth through technological advancements and collaborative efforts, addressing cost barriers and regulatory challenges will be crucial. Innovation in treatment modalities and data-driven approaches will pave the way for significant breakthroughs, facilitating business growth and improved patient care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pancreatic Cancer Therapeutics Market

The Pancreatic Cancer Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of pancreatic cancer cases across the world
  • Government initiatives to expand access to pancreatic cancer treatment options
• Market Restraints
  • Adverse drug recalls and difficulty in availing reimbursement options
• Market Opportunities
  • Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
  • Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
• Market Challenges
  • Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals

Porter's Five Forces: A Strategic Tool for Navigating the Pancreatic Cancer Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pancreatic Cancer Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pancreatic Cancer Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pancreatic Cancer Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pancreatic Cancer Therapeutics Market

A detailed market share analysis in the Pancreatic Cancer Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pancreatic Cancer Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pancreatic Cancer Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Pancreatic Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amgen Inc., Ascentage Pharma Group, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Carl Zeiss AG, Carrick Therapeutics Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Faeth Therapeutics, Inc., FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., GenesisCare, GlaxoSmithKline PLC, Hetero Healthcare Limited, ImmunityBio, Inc., Innovent Biologics Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mitsubishi Heavy Industries, Ltd., NGM Biopharmaceuticals, Inc., NovalGen, Novartis AG, PanTher Therapeutics, Inc., Pfizer, Inc., RenovoRx, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zentalis Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Pancreatic Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Endocrine Pancreatic Cancer and Exocrine Pancreatic Cancer.
• Based on Product, market is studied across Chemotherapy, Gene Therapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
• Based on End-Use, market is studied across Cancer Centers/Clinics, Hospitals, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of pancreatic cancer cases across the world
    • 5.1.1.2. Government initiatives to expand access to pancreatic cancer treatment options
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse drug recalls and difficulty in availing reimbursement options
  • 5.1.3. Opportunities
    • 5.1.3.1. Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
    • 5.1.3.2. Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer
  • 5.2.2. Product: Expanding number of approvals for chemotherapy treatment options
  • 5.2.3. End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pancreatic Cancer Therapeutics Market, by Type

• 6.1. Introduction
• 6.2. Endocrine Pancreatic Cancer
• 6.3. Exocrine Pancreatic Cancer

7. Pancreatic Cancer Therapeutics Market, by Product

• 7.1. Introduction
• 7.2. Chemotherapy
• 7.3. Gene Therapy
• 7.4. Immunotherapy
• 7.5. Radiation Therapy
• 7.6. Surgery
• 7.7. Targeted Therapy

8. Pancreatic Cancer Therapeutics Market, by End-Use

• 8.1. Introduction
• 8.2. Cancer Centers/Clinics
• 8.3. Hospitals
• 8.4. Research Institutes

9. Americas Pancreatic Cancer Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Pancreatic Cancer Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Pancreatic Cancer Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
  • 12.3.2. Lisata Receives Orphan Drug Designation For Pancreatic Cancer Therapy
  • 12.3.3. PanCAN Announces New & Advanced Research Investment
  • 12.3.4. Prestige Biopharma and Imagion Biosystems Sign Partnership Agreement to Develop Early Pancreatic Cancer Diagnosis Platform
  • 12.3.5. TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
  • 12.3.6. Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
  • 12.3.7. Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
  • 12.3.8. FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer
  • 12.3.9. FDA Clears TME Pharma's IND for Pancreatic Cancer Therapy Trial
  • 12.3.10. GenesisCare Launches ViewRay MRIdian MRI-Guided Radiation Therapy System at Lee Health Regional Cancer Center
  • 12.3.11. USD 3 Million National Grant to Fund Pancreatic Cancer Study
  • 12.3.12. Leap Therapeutics Acquires Flame Biosciences
  • 12.3.13. Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
  • 12.3.14. Faeth Therapeutics Raises USD 47 million to Advance Clinical Trials for Cancer
  • 12.3.15. AstraZeneca-Merck's Lynparza Wins EU Approval for Pancreatic Cancer

Companies Mentioned

• 1. Abbvie Inc.
• 2. Amgen Inc.
• 3. Ascentage Pharma Group
• 4. Astellas Pharma Inc.
• 5. AstraZeneca PLC
• 6. Bristol-Myers Squibb Company
• 7. C.H. Boehringer Sohn AG & Co. KG
• 8. Carl Zeiss AG
• 9. Carrick Therapeutics Limited
• 10. Cipla Limited
• 11. Dr. Reddy's Laboratories Ltd.
• 12. Eli Lilly and Company
• 13. F. Hoffmann-La Roche AG
• 14. Faeth Therapeutics, Inc.
• 15. FUJIFILM Holdings Corporation
• 16. GE HealthCare Technologies, Inc.
• 17. GenesisCare
• 18. GlaxoSmithKline PLC
• 19. Hetero Healthcare Limited
• 20. ImmunityBio, Inc.
• 21. Innovent Biologics Inc.
• 22. Johnson & Johnson Services, Inc.
• 23. Lupin Limited
• 24. Merck & Co., Inc.
• 25. Mitsubishi Heavy Industries, Ltd.
• 26. NGM Biopharmaceuticals, Inc.
• 27. NovalGen
• 28. Novartis AG
• 29. PanTher Therapeutics, Inc.
• 30. Pfizer, Inc.
• 31. RenovoRx, Inc.
• 32. Sun Pharmaceutical Industries Ltd.
• 33. Teva Pharmaceutical Industries Ltd.
• 34. Zentalis Pharmaceuticals, Inc.